DNA Ploidy, Nuclear Size, Proliferation Index and DNA-hypomethylation in Ovarian Cancer

Overview

Journal Gynecol Oncol

Date 2011 Jan 22

PMID 21251700

Citations 33

Authors

Alain G Zeimet

Heidi Fiegl

Georg Goebel

Francis Kopp

Claude Allasia

Daniel Reimer

Ilona Steppan

Elisabeth Mueller-Holzner

Melanie Ehrlich

Christian Marth

Affiliations

Soon will be listed here.

Abstract

Objective: The present study was undertaken to analyze the impact of epigenetic alterations with a main focus on nuclear area, aneuploidy, hyperploidy, and proliferation in 70 ovarian cancer specimens.

Methods: Morphometric changes and somatic chromosomal ploidy status were assessed by Feulgen spectrophotometry. DNA-hypomethylation of LINE1 repeats was analyzed by means of MethyLight PCR, and methylation levels of satellite 2 (Sat2) and satellite alpha (Satα) DNA sequences in chromosome 1 were measured by Southern blot analysis. These parameters were analyzed with regard to correlations as well as to recurrence and survival.

Results: We identified a significant association between LINE1 DNA-hypomethylation and patient age (p=0.029). Furthermore, LINE1 DNA-hypomethylation was positively correlated with the nuclear area (r=0.47; p<0.001) and the proliferation index (r=0.36; p<0.001). Univariate survival analysis showed that the nuclear area and LINE1 DNA-hypomethylation were prognostic factors for overall (p=0.015 and =0.006, respectively) and progression-free survival (p=0.020 and p=0.001 respectively), the percentage of aneuploidy only for overall survival (p=0.031). Subgroup survival analyses revealed that the prognostic value of these factors is strictly confined to mucinous cancers. In serous cancers no prognostic value could be pointed out for any analyzed parameter. Multivariate analysis of the entire cohort showed that the percentage of hyperploidy was an independent prognostic parameter for overall survival (p=0.003) and LINE1 DNA-hypomethylation for progression-free survival (p=0.03). In mucinous cancers nuclear area and LINE1 DNA-hypomethylation were found to be independent predictors of progression-free and overall survival.

Conclusions: In this study we identified the correlations between early cancer-associated genome DNA-hypomethylation, nuclear morphometric changes, somatic chromosomal ploidy status and the proliferation index. Prognostic relevance of nuclear area and LINE1 DNA-hypomethylation was revealed exclusively in mucinous ovarian cancers.

Citing Articles

Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.

Villagomez F, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick H, Webb P bioRxiv. 2024; .

PMID: 39282307 PMC: 11398366. DOI: 10.1101/2024.09.04.611120.

Patterns of Aneuploidy and Signaling Consequences in Cancer.

Zhakula-Kostadinova N, Taylor A Cancer Res. 2024; 84(16):2575-2587.

PMID: 38924459 PMC: 11325152. DOI: 10.1158/0008-5472.CAN-24-0169.

Repeat DNA methylation is modulated by adherens junction signaling.

Brenner L, Meyer F, Yang H, Kohler A, Bashtrykov P, Guo M Commun Biol. 2024; 7(1):286.

PMID: 38454140 PMC: 10920906. DOI: 10.1038/s42003-024-05990-4.

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms.

Wlodarczyk M, Ciebiera M, Nowicka G, Lozinski T, Ali M, Al-Hendy A Nutrients. 2024; 16(4).

PMID: 38398883 PMC: 10893337. DOI: 10.3390/nu16040559.

The prognostic role of single cell invasion and nuclear diameter in early oral tongue squamous cell carcinoma.

Almangush A, Hagstrom J, Haglund C, Kowalski L, Coletta R, Makitie A BMC Cancer. 2024; 24(1):213.

PMID: 38360653 PMC: 10870554. DOI: 10.1186/s12885-024-11954-y.

References

Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H . Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol. 2001; 84(1):21-31. DOI: 10.1006/gyno.2001.6440. View

Pfisterer J, Kommoss F, Sauerbrei W, Renz H, Bois A, Pfleiderer A . Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. 1994; 74(9):2509-15. DOI: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f. View

Coley H, Sargent J, Titley J, Taylor C . Lack of prognostic significance of ploidy and S-phase measurements in advanced ovarian cancer. Anticancer Res. 1999; 19(3A):2111-6. View

Eads C, Danenberg K, Kawakami K, Saltz L, Blake C, Shibata D . MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000; 28(8):E32. PMC: 102836. DOI: 10.1093/nar/28.8.e32. View

Hanada M, Delia D, Aiello A, Stadtmauer E, Reed J . bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993; 82(6):1820-8. View

Weisenberger D, Campan M, Long T, Kim M, Woods C, Fiala E . Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005; 33(21):6823-36. PMC: 1301596. DOI: 10.1093/nar/gki987. View

Narayan A, Ji W, Zhang X, Marrogi A, Graff J, Baylin S . Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer. 1998; 77(6):833-8. DOI: 10.1002/(sici)1097-0215(19980911)77:6<833::aid-ijc6>3.0.co;2-v. View

Eden A, Gaudet F, Waghmare A, Jaenisch R . Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003; 300(5618):455. DOI: 10.1126/science.1083557. View

Jintaridth P, Mutirangura A . Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Genomics. 2010; 41(2):194-200. DOI: 10.1152/physiolgenomics.00146.2009. View

10.

Ehrlich M, Hopkins N, Jiang G, Dome J, Yu M, Woods C . Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genet Cytogenet. 2003; 141(2):97-105. DOI: 10.1016/s0165-4608(02)00668-4. View

11.

Velthoven R, Petein M, Oosterlinck W, Zandona C, Zlotta A, van der Meijden A . Image cytometry determination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder cell carcinomas. Hum Pathol. 1995; 26(1):3-11. DOI: 10.1016/0046-8177(95)90108-6. View

12.

Lipsanen V, Leinonen P, Alhonen L, Janne J . Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia. Blood. 1988; 72(6):2042-4. View

13.

Esteller M, Herman J . Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2001; 196(1):1-7. DOI: 10.1002/path.1024. View

14.

Bol M, Baak J, Rep S, Marx W, Kruse A, Bos S . Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. Urology. 2002; 60(6):1124-30. DOI: 10.1016/s0090-4295(02)01906-4. View

15.

Yusup A, Kanamaru H, Aoki Y, Saikawa S, Moriyama N, Oyama N . Prognostic value of nuclear area index in patients with bladder cancer. Int J Urol. 2004; 11(6):374-8. DOI: 10.1111/j.1442-2042.2004.00813.x. View

16.

Blumenfeld D, Braly P, Klevecz R . Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecol Oncol. 1987; 27(3):389-402. DOI: 10.1016/0090-8258(87)90264-2. View

17.

Jones P, Veenstra G, Wade P, Vermaak D, Kass S, Landsberger N . Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998; 19(2):187-91. DOI: 10.1038/561. View

18.

Nan X, Campoy F, Bird A . MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997; 88(4):471-81. DOI: 10.1016/s0092-8674(00)81887-5. View

19.

Barnabei V, Miller D, Bauer K, Murad T, Rademaker A, Lurain J . Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol. 1990; 162(6):1584-90; discussion 1590-2. DOI: 10.1016/0002-9378(90)90924-v. View

20.

Colomb E, Kopp F, Spyratos F, Martin P . Cell-cycle studies by multiparametric automatic scanning of topographically preserved cells in culture. Cytometry. 1989; 10(3):263-72. DOI: 10.1002/cyto.990100305. View